ESPO® / NESP® / Aranesp®
ESPO® is a glycoprotein, human erythropoietin, produced by using the technology of genetic recombination. Its specific pharmacological effect of increasing erythrocytes allows it to act as an anemia-relieving treatment for renal anemia.
NESP®/Aranesp® is an erythropoiesis stimulating agent (ESA) with longer-lasting effect than conventional erythropoietin drugs. It is effective for improving renal anemia with reduced administration frequency. Merits including outstanding effectiveness in correcting anemia, along with a flexible dosage amount and interval, have earned the trust of the pharmaceutical marketplace and given this useful drug a leading market share.
The Information on this website regarding Aranesp®, erythropoietin and ESAs is not intended for audiences outside of, or to imply indications not approved in, the countries listed below. Aranesp® is a registered trademark of Amgen Inc.
Marketed by Kyowa Hakko Kirin in
|NESP®||Japan, Korea, Singapore, Taiwan, Thailand, Malaysia, Hong Kong, Macau|
|Aranesp®||Hong Kong, Macau|